QER/LAC@GDEAP−TLs demonstrated superior efficacy in in vivo tumor inhibition, suggesting that LAC-mediated rapid enzymatic activation of QER at the tumor site may represent a promising strategy for targeted cancer therapy [32]. Here, LCT is linked to neoplasm.